ClinicalTrials.gg
CompletedNCT06450366Updated Mar 27, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

A Phase 3 interventional study of Enlicitide and Ezetimibe in Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Completed at 35 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing enlicitide in Hypercholesterolemia — 1 open to participants now, 3 under way, 3 of them phase 3. enlicitide · Hypercholesterolemia.

Enrollment
6th of 10
301 · median 302
Started
2024
with 1 other
Phase 3
6 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
10 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing enlicitide in Hypercholesterolemia, this one is the 6th largest by enrollment, is one of 2 that started in 2024, is one of 6 in phase 3, and was the 6th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 10 studies testing enlicitide in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About enlicitide

enlicitide: first FDA approval 2026 (LIPFENDRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing enlicitide in Hypercholesterolemia, or all of them as a file.
02

Study summary

The main purpose of this study is to assess whether enlicitide is superior to ezetimibe or bempedoic acid or ezetimibe + bempedoic acid in reducing low-density lipoprotein cholesterol (LDL-C) in participants with hypercholesterolemia, and to evaluate its safety and tolerability. The primary study hypotheses are enlicitide is superior to ezetimibe, bempedoic acid, and ezetimibe + bempedoic acid on mean percent change from baseline in LDL-C at week 8.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has either a) history of a major atherosclerotic cardiovascular disease (ASCVD) event or b) if no history of a major ASCVD event, has intermediate to high risk for development of a first major ASCVD event
  • Has fasted lipid values (evaluated by the central laboratory) at Visit 1 (Screening) as follows: a) history of a major ASCVD event with LDL-C ≥55 mg/dL (≥1.42 mmol/L) OR b) No history of a major ASCVD event with low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (≥1.81 mmol/L)
  • Is treated with a low, moderate, or high intensity statin (±non-statin lipid lowering therapy [LLT])
  • Is on a stable dose of all background LLTs with no planned medication or dose changes during the study
  • Is an individual of any sex/gender, from 18 years of age inclusive, at the time of providing the

Exclusion criteria

Exclusion Criteria:

  • Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous familial hypercholesterolemia (HeFH), or double HeFH
  • Has class IV heart failure, or last known ≤25% by any imaging method, or had a heart failure hospitalization within 3 months before Visit 1 (Screening)
  • Participants with a history of tendon disorder or tendon rupture
  • Participants with a history of gout
  • Is undergoing or previously underwent an LDL-C apheresis program within 3 months before Visit 1 (Screening) or plans to initiate an LDL-C apheresis program
  • Was previously treated/is being treated with certain other cholesterol lowering medications, including ezetimibe, bempedoic acid, or protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors without adequate
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
301 participants (actual)

Study arms

  • Experimental
    Enlicitide

    Participants receive enlicitide 20mg, ezetimibe-matching placebo, and bempedoic acid-matching placebo once daily (QD) orally up to approximately 56 days.

    Drug: Enlicitide · Other: Placebo for Ezetimibe · Other: Placebo for Bempedoic Acid

  • Active comparator
    Ezetimibe

    Participants receive ezetimibe 10mg, enlicitide-matching placebo, and bempedoic acid-matching placebo QD orally up to approximately 56 days.

    Drug: Ezetimibe · Other: Placebo for Enlicitide · Other: Placebo for Bempedoic Acid

  • Active comparator
    Bempedoic Acid

    Participants receive bempedoic acid 180mg, ezetimibe-matching placebo, and enlicitide-matching placebo QD orally up to approximately 56 days.

    Drug: Bempedoic Acid · Other: Placebo for Enlicitide · Other: Placebo for Ezetimibe

  • Active comparator
    Ezetimibe + Bempedoic Acid

    Participants receive ezetimibe 10 mg, bempedoic acid 180mg, enlicitide-matching placebo orally QD for approximately 56 days.

    Drug: Ezetimibe · Drug: Bempedoic Acid · Other: Placebo for Enlicitide

Interventions

  • Oral tablet

    Also known as: MK-0616, Enlicitide Decanoate

  • Oral tablet

  • Oral capsule

  • OtherPlacebo for Enlicitide

    enlicitide-matching placebo oral tablet

  • OtherPlacebo for Ezetimibe

    ezetimibe-matching placebo oral tablet

  • OtherPlacebo for Bempedoic Acid

    bempedoic acid-matching placebo oral capsule

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56

    Blood samples were collected at baseline and after 56 days of treatment to assess mean percentage change in LDL-C. The mean percent change from baseline in LDL-C at Day-56 is reported.

    Time frame: Baseline and Day 56

Secondary outcomes

  1. Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 56

    Blood samples were collected at baseline and on day 56 of treatment to assess mean percent change in ApoB. The mean percent change from baseline in ApoB at Day 56 is reported.

    Time frame: Baseline and Day 56

  2. Mean Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Day 56

    Blood samples were collected at baseline and on day 56 of treatment to assess mean percent change in non-HDL-C. The mean percent change from baseline in non-HDL-C at 56 days is reported.

    Time frame: Baseline and Day 56

  3. Median Percent Change From Baseline in Lipoprotein(a) Levels (Lp[a])

    Blood samples were collected at baseline and on day 56 of treatment to assess median percent change in Lp(a) levels. The median percent change from baseline at Day 56 is reported.

    Time frame: Baseline and Day 56

  4. Percentage of Participants Who at Day 56 Have an LDL-C <70 mg/dL and ≥50% Reduction From Baseline

    Blood samples were collected at baseline and after 56 days of treatment to assess the percentage of participants who have an LDL-C \<70 mg/dL and ≥50% reduction from baseline at day 56. The percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline is reported.

    Time frame: Baseline and Day 56

  5. Percentage of Participants Who at Day 56 Have an LDL-C <55 mg/dL and ≥50% Reduction From Baseline

    Blood samples were collected at baseline and after 56 days of treatment to assess the percentage of participants who have an LDL-C \<55 mg/dL and ≥50% reduction from baseline at day 56. The percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline is reported.

    Time frame: Baseline and Day 56

  6. Percentage of Participants With ≥1 Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.

    Time frame: Up to approximately 147 days

  7. Percentage of Participants Discontinuing From Study Intervention Due to AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE is reported.

    Time frame: Up to approximately 91 days

07

Results

Posted Mar 27, 2026

Participant flow

Participant flow — Overall Study
MilestoneEnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic Acid
Started1015050100
Completed1004850100
Not completed1200
Withdrew: Participant moved0100
Withdrew: Withdrawal by subject1100

Outcome measures

PrimaryMean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56

Blood samples were collected at baseline and after 56 days of treatment to assess mean percentage change in LDL-C. The mean percent change from baseline in LDL-C at Day-56 is reported.

Time frame:
Baseline and Day 56
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56
Percent ChangeEnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic Acid
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 56-64.6 (-68.3 to -60.9)-6.3 (-13.5 to 0.8)-27.8 (-32.3 to -23.4)-36.5 (-40.8 to -32.2)
Statistical analysis
  • Enlicitide vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in means: -56.7 · 95% CI -64.3 to -49.0Difference in LS means between treatment groups (Enlicitide 20 mg - Bempedoic acid 180 mg) is estimated based on the washout and bootstrap (W\&B) imputation method through the ANCOVA model with treatment as a fixed effect and baseline as a covariate.
  • Enlicitide vs Ezetimibe · ANCOVA · p = <0.001 · Difference in means: -36.0 · 95% CI -41.8 to -30.2Difference in LS means between treatment groups (Enlicitide 20 mg - Ezetimibe 10 mg) is estimated based on the washout and bootstrap imputation method through the ANCOVA model with treatment as a fixed effect and baseline as a covariate.
  • Enlicitide vs Ezetimibe + Bempedoic Acid · ANCOVA · p = <0.001 · Difference in means: -28.1 · 95% CI -33.6 to -22.6Difference in LS means between treatment groups (Enlicitide 20 mg - Ezetimibe 10 mg and Bempedoic acid 180 mg) is estimated based on the W\&B imputation method through the ANCOVA model with treatment as a fixed effect and baseline as a covariate.
SecondaryMean Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 56

Blood samples were collected at baseline and on day 56 of treatment to assess mean percent change in ApoB. The mean percent change from baseline in ApoB at Day 56 is reported.

Time frame:
Baseline and Day 56
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 56
Percent ChangeEnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic Acid
Mean Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 56-54.6 (-57.6 to -51.6)-5.4 (-10.3 to -0.5)-20.2 (-23.3 to -17.2)-27.7 (-31.1 to -24.3)
Statistical analysis
  • Enlicitide vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in means: -47.5 · 95% CI -52.9 to -42.1Difference in LS means between treatment groups (Enlicitide 20 mg - Bempedoic acid 180 mg) is estimated based on the washout and bootstrap imputation method through the ANCOVA model with treatment as a fixed effect and baseline as a covariate.
  • Enlicitide vs Ezetimibe · ANCOVA · p = <0.001 · Difference in means: -33.6 · 95% CI -38.0 to -29.2Difference in LS means between treatment groups (Enlicitide 20 mg - Ezetimibe 10 mg) is estimated based on the washout and bootstrap imputation method through the ANCOVA model with treatment as a fixed effect and baseline as a covariate.
  • Enlicitide vs Ezetimibe + Bempedoic Acid · ANCOVA · p = <0.001 · Difference in means: -26.8 · 95% CI -31.2 to -22.5Difference in LS means between treatment groups (Enlicitide 20 mg - Ezetimibe 10 mg and Bempedoic acid 180 mg) is estimated based on the W\&B imputation method through the ANCOVA model with treatment as a fixed effect and baseline as a covariate.
SecondaryMean Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Day 56

Blood samples were collected at baseline and on day 56 of treatment to assess mean percent change in non-HDL-C. The mean percent change from baseline in non-HDL-C at 56 days is reported.

Time frame:
Baseline and Day 56
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Day 56
Percent ChangeEnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic Acid
Mean Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Day 56-58.0 (-61.3 to -54.7)-5.2 (-11.5 to 1.1)-25.1 (-28.7 to -21.6)-31.8 (-35.8 to -27.9)
Statistical analysis
  • Enlicitide vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in means: -51.2 · 95% CI -57.9 to -44.4Difference in LS means between treatment groups (Enlicitide 20 mg - Bempedoic acid 180 mg) is estimated based on the washout and bootstrap imputation method through the ANCOVA model with treatment as a fixed effect and baseline as a covariate.
  • Enlicitide vs Ezetimibe · ANCOVA · p = <0.001 · Difference in means: -32.2 · 95% CI -37.1 to -27.2Difference in LS means between treatment groups (Enlicitide 20 mg - Ezetimibe 10 mg) is estimated based on the washout and bootstrap imputation method through the ANCOVA model with treatment as a fixed effect and baseline as a covariate.
  • Enlicitide vs Ezetimibe + Bempedoic Acid · ANCOVA · p = <0.001 · Difference in means: -25.8 · 95% CI -30.7 to -20.8Difference in LS means between treatment groups (Enlicitide 20 mg - Ezetimibe 10 mg and Bempedoic acid 180 mg) is estimated based on the W\&B imputation method through the ANCOVA model with treatment as a fixed effect and baseline as a covariate.
SecondaryMedian Percent Change From Baseline in Lipoprotein(a) Levels (Lp[a])

Blood samples were collected at baseline and on day 56 of treatment to assess median percent change in Lp(a) levels. The median percent change from baseline at Day 56 is reported.

Time frame:
Baseline and Day 56
Reported as:
Median · Percent Change
Median Percent Change From Baseline in Lipoprotein(a) Levels (Lp[a])
Percent ChangeEnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic Acid
Median Percent Change From Baseline in Lipoprotein(a) Levels (Lp[a])-26.2 (-84.4 to 12.7)8.1 (-94.2 to 103.3)0.0 (-27.4 to 47.0)10.4 (-50.5 to 321.8)
SecondaryPercentage of Participants Who at Day 56 Have an LDL-C <70 mg/dL and ≥50% Reduction From Baseline

Blood samples were collected at baseline and after 56 days of treatment to assess the percentage of participants who have an LDL-C \<70 mg/dL and ≥50% reduction from baseline at day 56. The percentage of participants who have LDL-C \<70 mg/dL and ≥50% reduction from baseline is reported.

Time frame:
Baseline and Day 56
Reported as:
Number · Percentage of Participants
Percentage of Participants Who at Day 56 Have an LDL-C <70 mg/dL and ≥50% Reduction From Baseline
Percentage of ParticipantsEnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic Acid
Percentage of Participants Who at Day 56 Have an LDL-C <70 mg/dL and ≥50% Reduction From Baseline81.22.08.022.0
SecondaryPercentage of Participants Who at Day 56 Have an LDL-C <55 mg/dL and ≥50% Reduction From Baseline

Blood samples were collected at baseline and after 56 days of treatment to assess the percentage of participants who have an LDL-C \<55 mg/dL and ≥50% reduction from baseline at day 56. The percentage of participants who have LDL-C \<55 mg/dL and ≥50% reduction from baseline is reported.

Time frame:
Baseline and Day 56
Reported as:
Number · Percentage of participants
Percentage of Participants Who at Day 56 Have an LDL-C <55 mg/dL and ≥50% Reduction From Baseline
Percentage of participantsEnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic Acid
Percentage of Participants Who at Day 56 Have an LDL-C <55 mg/dL and ≥50% Reduction From Baseline78.22.08.020.0
SecondaryPercentage of Participants With ≥1 Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.

Time frame:
Up to approximately 147 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With ≥1 Adverse Event (AE)
Percentage of ParticipantsEnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic Acid
Percentage of Participants With ≥1 Adverse Event (AE)39.638.036.045.0
SecondaryPercentage of Participants Discontinuing From Study Intervention Due to AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE is reported.

Time frame:
Up to approximately 91 days
Reported as:
Number · Percentage of participants
Percentage of Participants Discontinuing From Study Intervention Due to AE
Percentage of participantsEnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic Acid
Percentage of Participants Discontinuing From Study Intervention Due to AE2.04.00.04.0

Adverse events

Collected over Death and adverse events up to 147 Days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enlicitide 20 mg0/101 (0%)0/101 (0%)0/101 (0%)
Bempedoic Acid 180 mg0/50 (0%)4/50 (8%)3/50 (6%)
Ezetimibe 10 mg0/50 (0%)1/50 (2%)3/50 (6%)
Ezetimibe 10 mg and Bempedoic Acid 180 mg0/100 (0%)0/100 (0%)0/100 (0%)
Most frequent serious events
Most frequent serious events
EventEnlicitide 20 mgBempedoic Acid 180 mgEzetimibe 10 mgEzetimibe 10 mg and Bempedoic Acid 180 mg
Myocardial infarctionCardiac disorders0/1010/501/500/100
Cholecystitis acuteHepatobiliary disorders0/1011/500/500/100
OverdoseInjury, poisoning and procedural complications0/1011/500/500/100
Transient ischaemic attackNervous system disorders0/1011/500/500/100
Mental disorderPsychiatric disorders0/1011/500/500/100
Most frequent other events
Most frequent other events
EventEnlicitide 20 mgBempedoic Acid 180 mgEzetimibe 10 mgEzetimibe 10 mg and Bempedoic Acid 180 mg
Accidental overdoseInjury, poisoning and procedural complications0/1013/503/500/100

Baseline characteristics

Age, Continuous
Age, Continuous(Years)EnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic AcidTotal
Mean64.3 ± 9.765.4 ± 10.265.4 ± 9.363.5 ± 10.964.4 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)EnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic AcidTotal
Female39181837112
Male62323263189
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic AcidTotal
Hispanic or Latino2512182883
Not Hispanic or Latino74383272216
Unknown or Not Reported20002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic AcidTotal
American Indian or Alaska Native00000
Asian2616142480
Native Hawaiian or Other Pacific Islander00000
Black or African American853521
White66293370198
More than one race00011
Unknown or Not Reported10001
Renal Function measured by estimated Glomerular Filtration Rate (eGFR)
Renal Function measured by estimated Glomerular Filtration Rate (eGFR)(Participants)EnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic AcidTotal
≥35 to <4520215
≥45 to <60943723
≥6090464592273
Mean low-density lipoprotein cholesterol (LDL-C) at Baseline
Mean low-density lipoprotein cholesterol (LDL-C) at Baseline(mg/dL)EnlicitideBempedoic AcidEzetimibeEzetimibe + Bempedoic AcidTotal
Mean89.9 ± 31.491.9 ± 24.493.2 ± 27.492.6 ± 33.491.6 ± 30.3
08

Study locations

35 sites
  • Clinical Trials Research ( Site 1509)
    Lincoln, California 95648, United States
  • Healthcare Research Network - Chicago ( Site 1507)
    Flossmoor, Illinois 60422, United States
  • L-MARC Research Center ( Site 1501)
    Louisville, Kentucky 40213, United States
  • Velocity Clinical Research Rockville ( Site 1503)
    Rockville, Maryland 20854, United States
  • Velocity Clinical Research, Gulfport ( Site 1505)
    Gulfport, Mississippi 39503, United States
  • Piedmont Research Partners ( Site 1506)
    Fort Mill, South Carolina 29707, United States
  • Rainier Clinical Research Center ( Site 1502)
    Renton, Washington 98057, United States
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 1002)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
  • CIPREC-CIPREC Sede Arenales ( Site 1000)
    Buenos Aires, Buenos Aires F.D. C1061AAS, Argentina
  • Fundacion Estudios Clinicos ( Site 1001)
    Rosario, Santa Fe Province S2000DEJ, Argentina
  • The Medical Arts Health Research Group ( Site 1606)
    Vancouver, British Columbia V7M 2H4, Canada
  • Cambridge Cardiac Care Centre ( Site 1603)
    Cambridge, Ontario N1R 6V6, Canada
  • North York Diagnostic and Cardiac Centre ( Site 1605)
    North York, Ontario M6B 3H7, Canada
  • Institut de Cardiologie de Montreal ( Site 1604)
    Montreal, Quebec H1T 1C8, Canada
  • Diex Recherche Trois-Rivieres ( Site 1602)
    Trois-Rivières, Quebec G9A 4P3, Canada
  • Hôpital Arnaud de Villeneuve - CHU Montpellier ( Site 0505)
    Montpellier, Herault 34090, France
  • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes-CIC Endocrinology-Diabetology-Nutrition ( Sit
    Nantes, Loire-Atlantique 44093, France
  • Hospices Civils de Lyon - Hopital Louis Pradel ( Site 0501)
    Bron, Rhone 69677, France
  • Hôpital Bichat - Claude-Bernard ( Site 0504)
    Paris, 75018, France
  • Yitzhak Shamir Medical Center. ( Site 0702)
    Beer Yaakov, 70300, Israel
  • Assuta Beersheba MC ( Site 0704)
    Beersheba, 8489507, Israel
  • Rambam Health Care Campus ( Site 0700)
    Haifa, 3109601, Israel
  • Meir Medical Center. ( Site 0703)
    Kfar Saba, 4428164, Israel
  • Hospital Universitario Virgen de la Victoria-UGC Endocrinologia y nutricion ( Site 0801)
    Málaga, Andalusia 29010, Spain
  • Hospital de Figueres ( Site 0804)
    Figueres, Gerona 17600, Spain
  • Hospital San Rafael de Coruna ( Site 0805)
    A Coruña, La Coruna 15006, Spain
  • EAP Sardenya ( Site 0800)
    Barcelona, 08025, Spain
  • Hospital Universitari Vall d'Hebron ( Site 0803)
    Barcelona, 08035, Spain
  • National Cheng Kung University Hospital-Internal Medicine ( Site 0403)
    Tainan, 704, Taiwan
  • National Taiwan University Hospital ( Site 0400)
    Taipei, 10002, Taiwan
  • Taipei Veterans General Hospital-Department of Medicine ( Site 0402)
    Taipei, 11217, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch ( Site 0404)
    Taoyuan, 33305, Taiwan
  • Barts Health NHS Trust-William Harvey Clinical Research Centre ( Site 0901)
    London, England EC1M 6BQ, United Kingdom
  • Royal Free Hospital ( Site 0900)
    London, England NW3 2QG, United Kingdom
  • National Institute for Health Research UCLH Clinical Research Facility ( Site 0908)
    London, London, City of NW1 2PG, United Kingdom
09

References and documents

Publications

  • Catapano AL, Mikhailova E, Navar AM, Banka P, Corral P, Saxena M, Steg PG, Verma S, Kordahi AY, Mendizabal G, Zhu P, Ballantyne CM; CORALreef AddOn Investigators. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. J Am Coll Cardiol. 2026 Jul 21;88(3):340-352. doi: 10.1016/j.jacc.2026.03.036. Epub 2026 Mar 30. PubMed 42017875 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Feb 2025, 7 months.

Results were first posted in Mar 2026, 1 year 1 month after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2024
First posted
Jun 10, 2024
StartActual
Jul 8, 2024
Primary completionActual
Feb 14, 2025
CompletionActual
Mar 28, 2025
Results first posted
Mar 27, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06450366
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
Jul 8, 2024
Primary completion
Feb 14, 2025
Completion
Mar 28, 2025
Results posted
Mar 27, 2026
Last update
Mar 27, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide

Start the discussion